search
Back to results

Vagal Nerve Stimulation for Treatment Resistant Major Depression

Primary Purpose

Major Depressive Disorder

Status
Active
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
gammaCore™
Sponsored by
University of Alabama at Birmingham
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Major Depressive Disorder

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Age 18-75 years old
  2. Sufficient fluency in English to understand testing procedures and provide written informed consent
  3. A Hamilton Depression Rating Scale total score greater than or equal 18
  4. A DSM 5 diagnosis of MDD based on the MINI

Exclusion Criteria:

  1. Evidence of alcohol or other substance use disorder in the past 3 months
  2. For females: current pregnancy or lactation (women of reproductive potential must have a negative urine pregnancy test at screening).
  3. Depressed patients who have failed at least one adequate antidepressant trial during the current depressive episode based on the ATRQ.
  4. Diagnosis of other primary psychiatric disorder (defined in this case as being the main focus of treatment) as determined by the MINI, such as: bipolar disorder, personality disorders, psychotic disorders, post-traumatic stress disorder, obsessive-compulsive disorder, dissociative disorders, eating disorder, or cognitive task due to neurological conditions
  5. Systolic blood pressure < 150 and/or diastolic blood pressure < 90 at screening
  6. Post-partum state (being within 2 months of delivery or miscarriage)
  7. Imminent suicide or homicide risk as determined by the investigator
  8. Being treated with one of the following medications: benzodiazepines or other CNS depressants.
  9. No clinically significant neurological disease based on medical history (e.g., epilepsy) or significant head injury.
  10. Any of the following disorders are exclusionary: Rheumatoid arthritis; Lupus erythematosus; Autoimmune hepatitis; Autoimmune peripheral neuropathy; Autoimmune pancreatitis; Behcet's disease; Crohn's disease; Autoimmune glomerulonephritis; Grave's disease; Guillain-Barre syndrome; Hashimoto's thyroiditis; Autoimmune polymyositis or polymyalgia; Myasthenia gravis; Narcolepsy; Polyarteritis nodosa; Scleroderma; Sjogren's syndrome; Transverse myelitis; Wegener's granulomatosis; History of seizures (only childhood febrile seizures are allowed)
  11. The presence of clinically significant laboratory findings in the opinion of the investigator including, but not limited to, clinically significant anemia or transaminase elevation is considered exclusionary.
  12. If the UDS is positive, the subject would be excluded if, in the opinion of the investigator, the positive UDS meant the subject has an active substance use disorder.
  13. Patients with prior exposure to VNS therapy whether using an implantable or external device will be excluded.
  14. An active implantable medical device, such as a pacemaker, hearing aid implant, or any implanted electronic device
  15. A metallic device, such as a stent, bone plate, or bone screw, implanted at or near the neck
  16. An open wound, rash, infection, swelling, cut, sore, drug patch, or surgical scar(s) on the neck at the treatment location
  17. Patients diagnosed with narrowing of the arteries (carotid atherosclerosis)
  18. Patients who have had surgery to cut the vagus nerve in the neck (cervical vagotomy)
  19. Patients with clinically significant hypertension, hypotension, bradycardia, or tachycardia

Sites / Locations

  • The University of Alabama at Birmingham

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Intervention Group

Arm Description

Treatment effects will be measured using standard rating scales including the HDRS-17, MADRS, SF-36, CSSR-S, CGI-I, CGI-S, which will be completed at each visit. The following scales will be completed at every other visit following the screening visit: Social Anhedonia Scale, the Motivation and Energy Inventory and the Physical Anhedonia Scale. At each study visit safety assessments including vital sign assessment and adverse event assessment will be completed. Subjects will also undergo physical examination and an ECG for safety during screening, after 8 weeks of treatment and at the end of 12 weeks of treatment.

Outcomes

Primary Outcome Measures

Antidepressant effects of nVNS in humans
Calculated by the Montgomery-Asberg Depression Rating Scale (MADRS): Each item has a severity scale from 0 to 6, with higher scores reflecting more severe symptoms. Ratings can be added to form an overall score (from 0 to 60). Snaith, Harrop, Newby, and Teale (1986) proposed the following cut-offs: scores of 0-6 indicate an absence of symptoms; 7-19 represent mild Depression; 20-34 moderate; 35-60 indicate severe Depression.
Incidence of gammaCore™ Adverse Events
gammaCore (nVNS) activates the vagus nerve with patented, gentle electrical stimulation. To assess potential changes in cognition, three computerized tests of cognition will the administered at baseline, Week 8, and Week 12. The Relational & Item Specific Encoding task (RISE) will probe any potential neural abnormalities. The Probabilistic Learning Task will be used to examine neural circuits related to reward processing in major depression disorder. For the working memory task, participants will be shown two images with objects and asked to decide whether the two images differ or not.

Secondary Outcome Measures

Full Information

First Posted
July 12, 2021
Last Updated
October 20, 2023
Sponsor
University of Alabama at Birmingham
search

1. Study Identification

Unique Protocol Identification Number
NCT04990687
Brief Title
Vagal Nerve Stimulation for Treatment Resistant Major Depression
Official Title
Vagal Nerve Stimulation for Treatment Resistant Major Depression
Study Type
Interventional

2. Study Status

Record Verification Date
October 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
January 1, 2022 (Actual)
Primary Completion Date
December 1, 2023 (Anticipated)
Study Completion Date
December 1, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Alabama at Birmingham

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this study is to 1) explore whether vagal nerve stimulation (nVNS) using a hand- held non-invasive device (gammaCore™) works to treat depression and 2) to confirm gammaCore™'s safety profile.
Detailed Description
The study will be up to 14 visits, which will occur for up to a 1 year period. The first visit is a screening visit, which will take about one hour to determine eligibility. If participants are eligible, participants will be scheduled for a baseline visit and 12 monthly visits to determine the antidepressant effects and possible side effects.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Major Depressive Disorder

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
5 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Intervention Group
Arm Type
Experimental
Arm Description
Treatment effects will be measured using standard rating scales including the HDRS-17, MADRS, SF-36, CSSR-S, CGI-I, CGI-S, which will be completed at each visit. The following scales will be completed at every other visit following the screening visit: Social Anhedonia Scale, the Motivation and Energy Inventory and the Physical Anhedonia Scale. At each study visit safety assessments including vital sign assessment and adverse event assessment will be completed. Subjects will also undergo physical examination and an ECG for safety during screening, after 8 weeks of treatment and at the end of 12 weeks of treatment.
Intervention Type
Device
Intervention Name(s)
gammaCore™
Intervention Description
Implantable VNS (iVNS), the electrical stimulation of the nervous system to modulate or modify function, has been FDA approved in the United States since the late 1990s. Implantable VNS therapy has been approved for use in epilepsy and depression. When treating major depression with implanted VNS, the widely held belief is that chronic stimulation is required for therapeutic effect. In trials of implantable VNS in major depression, more patients respond at 12 months than at 3 months. Once depressed patients respond to VNS, the effects have been demonstrated to continue for up to five years with continued stimulation. This finding suggests that VNS gradually changes brain function through neuroplasticity.
Primary Outcome Measure Information:
Title
Antidepressant effects of nVNS in humans
Description
Calculated by the Montgomery-Asberg Depression Rating Scale (MADRS): Each item has a severity scale from 0 to 6, with higher scores reflecting more severe symptoms. Ratings can be added to form an overall score (from 0 to 60). Snaith, Harrop, Newby, and Teale (1986) proposed the following cut-offs: scores of 0-6 indicate an absence of symptoms; 7-19 represent mild Depression; 20-34 moderate; 35-60 indicate severe Depression.
Time Frame
3 months
Title
Incidence of gammaCore™ Adverse Events
Description
gammaCore (nVNS) activates the vagus nerve with patented, gentle electrical stimulation. To assess potential changes in cognition, three computerized tests of cognition will the administered at baseline, Week 8, and Week 12. The Relational & Item Specific Encoding task (RISE) will probe any potential neural abnormalities. The Probabilistic Learning Task will be used to examine neural circuits related to reward processing in major depression disorder. For the working memory task, participants will be shown two images with objects and asked to decide whether the two images differ or not.
Time Frame
3 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age 18-75 years old Sufficient fluency in English to understand testing procedures and provide written informed consent A Hamilton Depression Rating Scale total score greater than or equal 18 A DSM 5 diagnosis of MDD based on the MINI Exclusion Criteria: Evidence of alcohol or other substance use disorder in the past 3 months For females: current pregnancy or lactation (women of reproductive potential must have a negative urine pregnancy test at screening). Depressed patients who have failed at least one adequate antidepressant trial during the current depressive episode based on the ATRQ. Diagnosis of other primary psychiatric disorder (defined in this case as being the main focus of treatment) as determined by the MINI, such as: bipolar disorder, personality disorders, psychotic disorders, post-traumatic stress disorder, obsessive-compulsive disorder, dissociative disorders, eating disorder, or cognitive task due to neurological conditions Systolic blood pressure < 150 and/or diastolic blood pressure < 90 at screening Post-partum state (being within 2 months of delivery or miscarriage) Imminent suicide or homicide risk as determined by the investigator Being treated with one of the following medications: benzodiazepines or other CNS depressants. No clinically significant neurological disease based on medical history (e.g., epilepsy) or significant head injury. Any of the following disorders are exclusionary: Rheumatoid arthritis; Lupus erythematosus; Autoimmune hepatitis; Autoimmune peripheral neuropathy; Autoimmune pancreatitis; Behcet's disease; Crohn's disease; Autoimmune glomerulonephritis; Grave's disease; Guillain-Barre syndrome; Hashimoto's thyroiditis; Autoimmune polymyositis or polymyalgia; Myasthenia gravis; Narcolepsy; Polyarteritis nodosa; Scleroderma; Sjogren's syndrome; Transverse myelitis; Wegener's granulomatosis; History of seizures (only childhood febrile seizures are allowed) The presence of clinically significant laboratory findings in the opinion of the investigator including, but not limited to, clinically significant anemia or transaminase elevation is considered exclusionary. If the UDS is positive, the subject would be excluded if, in the opinion of the investigator, the positive UDS meant the subject has an active substance use disorder. Patients with prior exposure to VNS therapy whether using an implantable or external device will be excluded. An active implantable medical device, such as a pacemaker, hearing aid implant, or any implanted electronic device A metallic device, such as a stent, bone plate, or bone screw, implanted at or near the neck An open wound, rash, infection, swelling, cut, sore, drug patch, or surgical scar(s) on the neck at the treatment location Patients diagnosed with narrowing of the arteries (carotid atherosclerosis) Patients who have had surgery to cut the vagus nerve in the neck (cervical vagotomy) Patients with clinically significant hypertension, hypotension, bradycardia, or tachycardia
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Matthew Macaluso, M.D.
Organizational Affiliation
The University of Alabama at Birmingham
Official's Role
Principal Investigator
Facility Information:
Facility Name
The University of Alabama at Birmingham
City
Birmingham
State/Province
Alabama
ZIP/Postal Code
35294
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
To be Determined

Learn more about this trial

Vagal Nerve Stimulation for Treatment Resistant Major Depression

We'll reach out to this number within 24 hrs